Type of chemotherapy has substantial effects on the immune system in ovarian cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Type of chemotherapy has substantial effects on the immune system in ovarian cancer
Authors
Keywords
Ovarian cancer, Chemotherapy, MDSC, Carboplatin-paclitaxel, Immunosuppression
Journal
Translational Oncology
Volume 14, Issue 6, Pages 101076
Publisher
Elsevier BV
Online
2021-03-24
DOI
10.1016/j.tranon.2021.101076
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
- (2019) Kathleen N Moore et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Combining conventional therapy with immunotherapy: A risky business?
- (2019) A. Coosemans et al. EUROPEAN JOURNAL OF CANCER
- Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
- (2019) Thaïs Baert et al. Frontiers in Immunology
- Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
- (2018) Allen W. Zhang et al. CELL
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
- (2018) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer
- (2016) Andreas Heindl et al. Oncotarget
- Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
- (2016) L. Galluzzi et al. Cancer Immunology Research
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer
- (2015) John B Liao et al. Journal for ImmunoTherapy of Cancer
- A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients
- (2014) Meiying Zhang et al. Journal of Ovarian Research
- Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment
- (2013) E. M. Dijkgraaf et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2
- (2013) Tracy X. Cui et al. IMMUNITY
- Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response
- (2012) C.-L. Chang et al. CANCER RESEARCH
- Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide
- (2011) F. Moschella et al. CANCER RESEARCH
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
- (2010) Carol Kilkenny et al. PLOS BIOLOGY
- Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
- (2009) Hanh K. Le et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
- (2008) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More